Pancreatic Cancer Research

ResearcherIstanbul Medipol UniversityActive in the last 2 years

Ahmet Erkan Bilici

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0443-6966; OpenAlex author ID A5005099971. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
3
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 2 papers

Papers 3

  1. Claudin 18.2, IDH1, and neutrophil-to-lymphocyte ratio as prognostic biomarkers in unresectable pancreatic ductal adenocarcinoma receiving first-line chemother… Last author DOI 10.17305/bb.2026.14093↗
  2. Molecular Profiling and Survival Outcomes in Pancreatic Ductal Adenocarcinoma: A Multicenter Real-World Study from Turkey. Co-author DOI 10.3390/curroncol33040216↗
  3. Prognostic factors related with survival in patients with pancreatic adenocarcinoma. Co-author DOI 10.3748/wjg.v20.i31.10802↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ebru Karcı · 1 shared paper, 2026 · strength 0.32
  2. Mustafa Ozdogan · 1 shared paper, 2026 · strength 0.30
  3. Selami Bayram · 1 shared paper, 2026 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.